CatalentNYSE: CTLT

EU antitrust regulators have requested opinions from pharmaceutical competitors and clients regarding four business sectors due to Novo Holdings' proposed $16.5 billion acquisition of Catalent, according to sources familiar with the situation.

Catalent (CTLT) reported a quarterly loss of $0.13 per share, which is worse than the Zacks Consensus Estimate of $0.11. This is also a decline from a loss of $0.10 per share the previous year.

EU antitrust regulators are expected to make a decision by December 6 on whether to approve Novo Holdings' purchase of the contract drug manufacturer Catalent, as stated in a document on the European Commission's website on Monday.

Catalent's stock is experiencing uncertainty because many pharmaceutical companies are worried about possible reduced competition after the acquisition, particularly in the production of weight-loss medications.

CTLT has announced that it has reached an agreement to sell its facility in Somerset, which focuses on the development and manufacturing of oral solid medications, to Ardena.

Catalent announced on Monday that it will sell its facility in Somerset, New Jersey, which focuses on oral drug development and small-scale manufacturing, to the private contract drug manufacturer Ardena.

On October 14, 2024, in Ghent, Belgium, Ardena, a pharmaceutical Contract Development and Manufacturing Organisation (CDMO) with GMP facilities in several countries, announced that it has finalized an agreement to purchase Catalent's advanced facility in Somerset, New Jersey. This acquisition will greatly improve Ardena's ability to manufacture oral drug products on a smaller scale during the later stages of development. It aligns with Ardena's goal to become a top global CDMO that provides comprehensive solutions throughout the pharmaceutical development process.

U.S. Senator Elizabeth Warren has urged antitrust regulators to carefully examine a $16.5 billion agreement where Novo Nordisk's main shareholder plans to buy contract drug maker Catalent. She believes this deal could provide the pharmaceutical company an unfair edge in the market for weight loss and obesity medications.

Catalent (CTLT) has received a Zacks Rank #1 (Strong Buy) upgrade, indicating increased confidence in the company's potential earnings. This could lead to a rise in the stock price in the short term.